We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Akero

News List

Akero Initiates Phase 2b HARMONY Study of Efruxifermin for NASH americanpharmaceuticalreview
March 01, 2021
Akero Therapeutics has screened the first patients for its Phase 2b HARMONY study evaluating efruxifermin (EFX), the company's lead product candidate for the treatment of NASH.
Akero Expands NASH Trial to Include Cohort of Cirrhotic Patients americanpharmaceuticalreview
January 19, 2020
Akero Therapeutics announced the ongoing Phase 2a BALANCED study of AKR-001 is being expanded to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have compensated cirrhosis (F4), Child-Pugh Class A.
Akero Announces Dosing of First Patient in NASH Study americanpharmaceuticalreview
July 04, 2019
Akero Therapeutics announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH (the BALANCED study).